Patient preference of trastuzumab administration (SC versus IV) in HER2-positive metastatic breast cancer: Results of the randomised Metaspher study

Pivot, Xavier; Spano, J. P.; Marc, Elisabeth; Cottu, P.; Jouannaud, Christelle; Pottier, V.; Moreau, L.; Jm, Extra; Lortholary, Alain; Rivera, P.; Spaëth, Dominique; Attar-Rabia, H.; Benkamoun, C.; Dima-Martinez, L.; Esposito, Nicole N.; Gligorov, J.

doi:10.1093/annonc/mdw365.53

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…was consistent with prior findings with trastuzumab iv. [60,61], as also recently confirmed in the final analysis of the HannaH Phase III trial in patients with early breast cancer, after a 6-year follow-up [81].…”

Section: Discussionsupporting

confidence: 59%

“…versus sc. administration, reported findings with trastuzumab therapy in patients with early or metastatic HER2-positive breast cancer [60,61]. Patients receiving trastuzumab sc.…”

Section: Discussionmentioning

confidence: 99%

“…and 44% of patients receiving trastuzumab iv. [61]. Among AEs observed with trastuzumab sc., 7% were grade ≥3 and 3% were serious AEs.…”

Section: Tolerability Outcomesmentioning

confidence: 99%

See 2 more Smart Citations

Humanistic and Economic Impact of Subcutaneous Versus Intravenous Administration of Oncology Biologics

et al. 2019

View full text Add to dashboard Cite

More oncology biologics are becoming available for subcutaneous (sc.) administration and are expected to provide useful therapeutic options. We evaluated evidence published in the past 5 years to assess the humanistic and economic impact of sc. versus intravenous administration of approved cancer therapies and identify outcomes favoring either administration route. These publications focused predominantly on healthcare resource utilization and economic outcomes, demonstrating resource and cost savings with sc. administration. Patients reported a better health-related quality of life and preference for sc. formulations. Time-and-motion study analyses confirmed the convenience of sc. administration. These findings suggest that future availability of sc. oncology biologics, especially anti-PD-1/PD-ligand 1 antibodies due to their increased utility in various malignancies, may be beneficial for patients, healthcare providers and payers.

show abstract

Section: Discussionsupporting

confidence: 59%

“…versus sc. administration, reported findings with trastuzumab therapy in patients with early or metastatic HER2-positive breast cancer [60,61]. Patients receiving trastuzumab sc.…”

Section: Discussionmentioning

confidence: 99%